Walleye Trading’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-300
| Closed | -$8.01K | – | 4045 |
|
|
2025
Q4 | $8.01K | Buy |
+300
| New | +$7.17K | ﹤0.01% | 4174 |
|
|
2025
Q3 | – | Sell |
-3,100
| Closed | -$66.9K | – | 4309 |
|
|
2025
Q2 | $66.9K | Buy |
+3,100
| New | +$57.6K | ﹤0.01% | 3744 |
|
|
2024
Q2 | – | Sell |
-13,000
| Closed | -$240K | – | 4187 |
|
|
2024
Q1 | $240K | Sell |
13,000
-5,200
| -29% | -$129K | ﹤0.01% | 3324 |
|
|
2023
Q4 | $570K | Buy |
18,200
+1,800
| +11% | +$43K | ﹤0.01% | 2966 |
|
|
2023
Q3 | $342K | Buy |
16,400
+3,700
| +29% | +$100K | ﹤0.01% | 3264 |
|
|
2023
Q2 | $304K | Hold |
12,700
| – | – | ﹤0.01% | 3138 |
|
|
2023
Q1 | $239K | Buy |
12,700
+10,800
| +568% | +$206K | ﹤0.01% | 3384 |
|
|
2022
Q4 | $30.2K | Buy |
1,900
+1,600
| +533% | +$25K | ﹤0.01% | 4302 |
|
|
2022
Q3 | $5K | Hold |
300
| – | – | ﹤0.01% | 4643 |
|
|
2022
Q2 | $4K | Sell |
300
-5,400
| -95% | -$101K | ﹤0.01% | 4820 |
|
|
2022
Q1 | $138K | Sell |
5,700
-8,000
| -58% | -$194K | ﹤0.01% | 4069 |
|
|
2021
Q4 | $320K | Sell |
13,700
-4,000
| -23% | -$80.5K | ﹤0.01% | 3430 |
|
|
2021
Q3 | $294K | Buy |
17,700
+9,500
| +116% | +$183K | ﹤0.01% | 3469 |
|
|
2021
Q2 | $200K | Buy |
+8,200
| New | +$185K | ﹤0.01% | 3922 |
|
|
2020
Q1 | – | Sell |
-129,700
| Closed | -$5.55M | – | 3895 |
|
|
2019
Q4 | $5.55M | Buy |
129,700
+120,400
| +1,295% | +$5.24M | 0.04% | 528 |
|
|
2019
Q3 | $335K | Sell |
9,300
-63,900
| -87% | -$1.94M | ﹤0.01% | 2486 |
|
|
2019
Q2 | $1.96M | Buy |
+73,200
| New | +$1.87M | 0.02% | 1060 |
|
|
2019
Q1 | – | Sell |
-9,500
| Closed | -$154K | – | 4110 |
|
|
2018
Q4 | $154K | Buy |
9,500
+9,400
| +9,400% | +$183K | ﹤0.01% | 3617 |
|
|
2018
Q3 | $2K | Buy |
+100
| New | +$1.57K | ﹤0.01% | 5181 |
|
|
2017
Q3 | – | Sell |
-100
| Closed | -$3 | – | 4029 |
|
|
2017
Q2 | $3 | Buy |
+100
| New | +$2.98K | ﹤0.01% | 4367 |
|
|
2017
Q1 | – | Sell |
-400
| Closed | -$12K | – | 4613 |
|
|
2016
Q4 | $12K | Sell |
400
-200
| -33% | -$5.29K | ﹤0.01% | 4248 |
|
|
2016
Q3 | $19K | Buy |
+600
| New | +$20.3K | ﹤0.01% | 4191 |
|
|
2016
Q2 | – | Sell |
-40,900
| Closed | -$1.14M | – | 5248 |
|
|
2016
Q1 | $1.14M | Buy |
40,900
+39,900
| +3,990% | +$870K | 0.01% | 1282 |
|
|
2015
Q4 | $36K | Buy |
+1,000
| New | +$35.2K | ﹤0.01% | 4075 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Walleye Trading's ACAD Position: Q1 2026 in Review
Walleye Trading sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 6,846 shares — an estimated $183K sold.
Walleye Trading first reported a position in ACAD in Q4 2015 and held it in 16 quarters. The position peaked at $683K in Q4 2021. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Walleye Trading reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Walleye Trading sold 6,846 Acadia Pharmaceuticals shares in Q1 2026, an estimated $183K.
- Walleye Trading first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 16 quarters.
- Walleye Trading's Acadia Pharmaceuticals position peaked at $683K in Q4 2021.
- 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.